Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types

重组脂质化 FLIPr 可有效增强各种疫苗类型的粘膜和全身免疫反应

阅读:6
作者:Ming-Shu Hsieh, Mei-Yu Chen, Chia-Wei Hsu, Yu-Wen Tsai, Fang-Feng Chiu, Cheng-Lung Hsu, Chang-Ling Lin, Chiao-Chieh Wu, Ling-Ling Tu, Chen-Yi Chiang, Shih-Jen Liu, Ching-Len Liao, Hsin-Wei Chen

Abstract

Formyl peptide receptor-like 1 inhibitor protein (FLIPr) is an immune evasion protein produced by Staphylococcus aureus, and FLIPr is a potential vaccine candidate for reducing Staphylococcus aureus virulence and biofilm formation. We produced recombinant lipidated FLIPr (rLF) to increase the immunogenicity of FLIPr and showed that rLF alone elicited potent anti-FLIPr antibody responses to overcome the FLIPr-mediated inhibition of phagocytosis. In addition, rLF has potent immunostimulatory properties. We demonstrated that rLF is an effective adjuvant. When an antigen is formulated with rLF, it can induce long-lasting antigen-specific immune responses and enhance mucosal and systemic antibody responses as well as broad-spectrum T-cell responses in mice. These findings support further exploration of rLF in the clinic as an adjuvant for various vaccine types with extra benefits to abolish FLIPr-mediated immunosuppressive effects.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。